Navigation Links
Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe
Date:3/19/2008

Diamyd Medical AB (http://www.omxgroup.com, OMX: DIAM B;

http://www.otcqx.com, OTC: DMYDY)

STOCKHOLM, Sweden, March 19 /PRNewswire-FirstCall/ -- Diamyd Medical (OMX: DIAM B)(OTC: DMYDY)announced today that the Swedish Medical Products Agency (MPA) has approved the Company's application to commence Phase III studies with the therapeutic diabetes vaccine Diamyd(R).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

"I am extremely glad that we now can offer our recently diagnosed type 1 diabetes patients the possibility to participate also in the European study," says Professor Johnny Ludvigsson, Linkoping, Sweden, Principal Investigator for the study.

Diabetes teams from approximately 20 Swedish pediatric clinics will meet in Linkoping, Sweden on April 4 to go through details for the study, which will comprise 306 new onset type 1 diabetes patients. Diamyd Medical is planning to file clinical trial applications in another 3-4 European countries and include additionally 20 clinics in the study.

"The approval from the Swedish MPA is another important step in the development of Diamyd(R) towards the market," says Elisabeth Lindner, President and CEO of Diamyd Medical. "Last week we received authorization from the FDA to start a parallel Phase III trial in the US, and together with TrialNet's planned study in the US, the interest in Diamyd is strong. We receive daily inquiries from parents of patients wanting to participate in our studies."

http://www.diamyd.com

Disclaimer: This document contains certain statements relating to the progress, timing and completion of our research, development and clinical trials. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.


'/>"/>
SOURCE Diamyd Medical AB (publ)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
2. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
3. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
4. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
5. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
6. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
7. Mayo Clinic Study Finds Further Association Between Diabetes and Pancreatic Cancer
8. Gastric Banding Reverses Impact of Type 2 Diabetes
9. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
10. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
11. Help! Im Sick. How Do I Handle My Diabetes?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
Breaking Medicine Technology:
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):